RxDoctor Payments Data

Bilal Saeed, MD

Interventional Cardiology · Oklahoma City, OKNPI 1083878342

Payments from drug & device makers

$6,341in general payments, 2019–2025

Across 60 payments — averaging $105.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$4K
  • Medtronic$908
  • Cardiovascular Systems Inc.$167
  • Abbott$160
  • Amgen$96
  • Novartis$79
  • plus $547 from 17 others

What the payments were for

  • Travel & lodging$4,47571%
  • Food & beverage$1,86729%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,341 in reported general payments places this provider in the 40th percentile of 110 interventional cardiology providers in Oklahoma.

See all interventional cardiology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$194,874
Medicare patients
816
Services billed
2,656

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban405$312,280
EntrestoSacubitril/Valsartan141$131,325
OzempicSemaglutide72$81,154
Repatha SureclickEvolocumab53$36,703
FarxigaDapagliflozin Propanediol29$23,924
JardianceEmpagliflozin29$21,200
MounjaroTirzepatide14$14,777
TradjentaLinagliptin13$11,027
Telmisartan292$6,875
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$5,410
Prasugrel Hcl79$4,085
CorlanorIvabradine Hcl12$3,903
Metoprolol Succinate311$3,530
Clonidine34$2,902
Torsemide203$2,315

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$26$312,280405 claims
NovartisEntresto$79$131,325141 claims
Novo NordiskOzempic$43$81,15472 claims
Boehringer IngelheimJardiance, Tradjenta$15$32,22742 claims
AstraZenecaFarxiga$37$23,92429 claims
AmgenCorlanor$96$3,90312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 110 interventional cardiology providers in Oklahoma.

Other interventional cardiology in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →